NCT05758519

A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,220 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A Phase 3 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	QLS1128	QLS1128
DRUG	Placebo	Placebo

Timeline

• Start date: 2023-03-07
• Primary completion: 2023-06-30
• Completion: 2023-06-30
• First posted: 2023-03-07
• Last updated: 2023-03-10

Locations

1 site across 1 country: China